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 Abstract
Background: Double-blind placebo controlled food challenge (DBPCFC) is the gold standard diagnostic test in food allergy because it 
minimizes diagnostic bias. 
Objective: To investigate the potential effect of diagnosis on the socioeconomic costs of food allergy.
Methods: A prospective longitudinal cost analysis study was conducted in Spain and Poland within the EuroPrevall project. Food-allergic 
patients were enrolled into the study and in all cases diagnosis was confirmed through a standardized DBPCFC. Data were collected 
through a self-administered survey on all aspects of health and social care resource use, costs of living, and costs of leisure activities. 
Costs were measured before and 6 months after the DBPCFC and reported in international dollars with 2007 as the benchmark year. 
Results: Forty-two patients were enrolled. Twenty-one patients had a negative DBPCFC and the suspected food was reintroduced into their 
diet. Comparing total direct costs before and after the DBPCFC, the reactive group spent a significantly higher amount (median increase 
of $813.1 over baseline), while the tolerant group’s spending decreased by a median of $87.3 (P=.031). The amount of money spent on 
food 6 months after diagnosis was also significantly higher in the reactive group (P=.040). Finally, a larger, but not statistically significant, 
decrease in total indirect costs was observed in the tolerant group compared with the reactive group ($538.3 vs $32.3). 
Conclusion: DBPCFC has an impact on indirect and direct costs of living. The main contribution to this increase was money spent on food.
Key words: Food allergy. Double-Blind Placebo-Controlled Food Challenge. Diagnosis. Socioeconomic impact.
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 Resumen
Introducción: La provocación oral doble ciego controlada con placebo (PODCCP) es prueba diagnóstica "gold standard" en alergia a 
alimentos. 
Objetivo: El objetivo de este estudio es investigar el efecto del diagnóstico en los costes socioeconómicos de la alergia a alimentos (AA). 
Métodos: Estudio prospectivo longitudinal de análisis de costes llevado a cabo en España y Polonia en el contexto de proyecto EuroPrevall. Se 
seleccionaron pacientes con AA y en todos los casos el diagnóstico fue estandarizado a través de una PODCCP estandarizada. Se utilizaron 
cuestionarios autoadministrados para recoger datos del uso de recursos sociosanitarios, coste de vida y coste de actividades de ocio. Los 
costes se midieron en dos puntos, antes y 6 meses después de PODCCP, expresados en dólares internacionales (nivel de costes 2007). 
Resultados: Se incluyeron 42 pacientes. 21 pacientes tuvieron una PODCCP negativa y se reintrodujo el alimento. Comparando los costes 
directos antes y después de PODCCP, el gasto en el grupo de pacientes reactivos fue significativamente mayor (mediana de incremento 
$813,1 a los 6 meses), mientras que en el grupo de pacientes tolerantes disminuyó una mediana de $87,3 (p=0,031). Los pacientes 
con una provocación positiva gastaron también más dinero en comida a los 6 meses del diagnóstico (p=0,040). Por último, los costes 
indirectos disminuyeron, aunque de forma no estadísticamente significativa, en el grupo de pacientes tolerantes comparado con los 
reactivos ($ 538,3 versus $32,3). 
Conclusión: La PODCCP tiene un impacto en los costes directos e indirectos, en su mayor parte debido al dinero gastado en comida.
Palabras clave: Alergia a alimentos. Provocación oral doble ciego controlada con placebo. Diagnóstico. Impacto socioeconómico.
Introduction
Food allergy is a major health problem affecting all 
age groups. Between 1% and 2% of adults and 5% and 
8% of children are estimated to have food allergy. These 
rates increase to 30% in studies where self-perceived food 
allergy is reported [1-5]. Once diagnosis is established, the 
only treatment consists of strict avoidance of the offending 
food, and patients return for regular follow-up visits and re-
evaluation [6,7]. Allergic individuals need to learn to identify 
and avoid products containing the problematic foods and 
ingredients, and be taught to deal with a reaction. This dietary 
management may have a considerable impact on social and 
family life due to the need for continuous vigilance [8]. 
The aim of EuroPrevall [9], a European Union–funded 
integrated project, is to provide information about the 
prevalence of food allergy. An important aspect of the project 
is to assess the socioeconomic impact of food allergy by linking 
clinical data with data related to economic costs [10]. This is a 
very relevant part of the project, as prior to EuroPrevall, very 
little was known about the socioeconomic consequences of 
food allergy [11,12].
Miles et al [12] developed a framework for the assessment 
of social and economic costs of food allergy. The authors 
were unable to identify previous work investigating such 
costs, although costs analyses have been performed for other 
allergic conditions, such as asthma, allergic rhinitis, eczema, 
latex allergy, and drug allergy. While some costs may be 
similar in food allergy and other allergic conditions, others 
may be specific to food allergy. Fox et al [11,13] developed 
a questionnaire for measuring costs of food allergy at the 
individual and household level. The questionnaire is available 
in Bulgarian, Czech, Dutch, French, German, Greek, Icelandic, 
Italian, Lithuanian, Polish, and Spanish. 
Double-blind placebo-controlled food challenge 
(DBPCFC) is considered the gold standard diagnostic test in 
food allergy [14] because it minimizes bias [15,16], although 
it is not used routinely in most clinical settings. One of the 
benefits of a positive challenge is the establishment of a 
conclusive diagnosis of food allergy, which goes hand in hand 
with the need for continued counselling regarding avoidance. 
Unlike the diagnosis of allergic conditions such as asthma, 
rhinitis, and hymenoptera venom allergy, a diagnosis of 
food allergy after a reaction has to be considered as merely 
presumptive, even in the presence of a positive skin prick 
test (SPT) or specific IgE (sIgE) [17]. Apart from confirming 
diagnosis, a positive DBPCFC also reduces anxiety about 
whether an individual is allergic or not, and validates patients’ 
or parents’ efforts to avoid problematic foods [8,18]. A negative 
DBPCFC is followed by an open exposure to the suspected 
food, allowing the patients to realize that they are tolerant and 
that avoidance is no longer necessary. Consequently, their diet 
is expanded, nutrition is improved, and the patient’s quality 
of life is enhanced. The main hypothesis of this paper is that 
the direct and indirect costs of living and of seeking health 
care will also change following confirmation of food allergy 
by DBPCFC. 
Methods
Study Population
To assess the effect of DBPCFC on socioeconomic costs, 
patients recruited to participate in the EuroPrevall cross-
sectional study in Madrid, (Spain) and Lodz (Poland) were in 
addition invited to enrol in this prospective longitudinal study 
nested in EuroPrevall. Recruitment occurred between October 
2007 and June 2009. Patients were evaluated in allergy clinics 
following the same protocol as those used in the clinical studies 
carried out in the EuroPrevall project [10,19]. A clinical history 
and blood samples for sIgE were obtained in all cases and SPTs 
were also performed. Diagnosis was subsequently established 
through a standardized DBPCFC. 
Data were collected through a patient self-administered 
expenditure and cost survey; in the case of pediatric patients, 
their parents completed the questionnaire. A detailed 
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Statistical Analysis
Direct and indirect costs were compared before and after 
the DBPCFC to detect possible differences between tolerant 
and reactive patients (or parents of tolerant and reactive 
children). Categorical variables were described using both 
absolute and relative frequencies. The distribution of cost data 
was strongly skewed and was therefore described by median 
and interquartile range (IQR). The effect of the DBPCFC 
was assessed by computing the difference between pre- and 
post-DBPCFC questionnaires. In other words, a positive 
value was interpreted as a cost increment. This difference was 
compared between the tolerant and reactive groups by means 
of the Mann-Whitney U test. All the tests were 2-tailed and 
the significance level was set a P value of .05. SPSS version 
15.0 was used for all statistical analyses. 
Results
Forty-two patients were followed up after the DBPCFC 
and information on costs was collected before the challenge 
and 6 months afterwards. The majority of patients (n=31) 
were children, with a median age of 3 years; the median age 
of respondents (including adult patients and parents) was 35 
years and the majority of households were formed by 2 adults 
and 1 or 2 children. The most frequently tested food was milk 
followed by egg (Table 1). In our cohort none of the patients 
were allergic to more than 2 foods.
description of the development of this questionnaire is 
provided elsewhere [11]. The questionnaire gathered structured 
information on all aspects of health and social care resource 
use, cost of living, and cost of leisure activities.
The questionnaire was distributed before and after the 
DBPCFC. Patients were invited to participate on the first day 
of the DBPCFC (baseline) and were re-evaluated 6 months 
later using the same instrument. After the challenge, new 
instructions were given to the patient. In the case of a negative 
result, they were told to include the previously suspected food 
in their diet and that avoidance was no longer necessary, and 
in the case of a positive result, they were advised to adhere to 
an avoidance diet. 
Survey
This cost analysis was approached from the patient’s 
perspective. To compare costs across countries, costs were 
calculated using the purchasing power parity (PPP) of the 
Geary-Khamis, or international, dollar with 2007 as the 
benchmark year [20]. Indirect costs were calculated using 
a method that assigns a monetary value to time loss due to 
household production. In the opportunity cost method each 
individual’s market wage rate was used to calculate this 
value [21]. The opportunity cost method is widely used in the 
literature and is well validated [22]. When a person was not 
in paid employment, the minimum wage rate of the patient’s 
country was used. When the person reported that they were 
working, but did not state their income, the national average 
wage was used. Total direct cost was calculated by adding 
all out-of-pocket cost items from the questionnaire. When no 
direct or indirect costs were incurred, zero cost was used in the 
analysis. When in previous questions it was stated that costs 
were incurred on a particular item without mentioning the 
amount, the cost item was entered as a missing value. 
Direct costs included medical treatment costs not covered 
by insurance (and thus paid by the individual); travel costs to 
obtain medical treatment; medication costs, including over-
the-counter (OTC) and prescription medicines (hydrolyzed 
formula was included in the cost of medication as it is covered 
by the national health system in both countries and hence is not 
considered a food cost); and costs of living, including food, 
holidays, leisure activities, equipment required to prepare safe 
meals, and outside domestic help. Indirect costs included lost 
working days, loss of education or working opportunities, 
lost leisure time, lost earnings, lost human capital, and time 
spent on shopping, cooking, household tasks, searching for 
information on health-related issues, and obtaining medical 
treatment (e.g., travel and visit time). 
Ethics
All participants received written information on the study 
together with the questionnaire. Participation was voluntary 
and independent of the individual’s contribution to the rest of 
the EuroPrevall protocols. All questionnaires were assigned 
unique codes to provide a data set with anonymous records. 
Only the researcher was able to match the unique codes with 
the personal data of the participants. Ethical approval was 
obtained from the participating centers in Spain and Poland. 
Table 1. Characteristics of Study Patients (n=42)a 
Food used in DBPCFC Egg 8 (19) 
 Milk 21(50) 
 Shrimp 1 (2.4) 
 Hazelnut 5 (11.9) 
 Peanut 1 (2.4) 
 Fruit (apple/peach) 6 (13.59)
Result of DBPCFC Positive 21 (50) 
 Negative 21 (50)
Sex Male 15 (35.7) 
 Female 27 (64.3
Median age, y Adultsb 35 
 Children 3
Country Spain 36 (85.7) 
 Poland 6 (14.3)  
aResults are reported as number (%) of patients, unless otherwise 
indicated. 
bIncludes parents with an allergic child (n=31) and adult allergic 
patients (n=11).
Table 2 and Table 3, respectively, show the direct and 
indirect costs at baseline. Tolerant and reactive patients were 
comparable in terms of total direct costs and individual costs 
of living and leisure activities. Tolerant patients spent more 
on OTC medication (P=.024). No differences were found 
for total indirect costs, lost leisure time, or costs assigned to 
time spent seeking health care or information. There were, 
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however, differences in the value assigned to time spent on 
household tasks (P=.047), which was higher in the tolerant 
group. Direct costs were divided into health care costs, costs 
of living, and leisure activity costs. The median of total direct 
costs was $3289.8 annually (IQR, $13.60-$11 207.60). The 
median amount spent on medication was $22.0 for prescription 
medication and $161.5 for OTC medication. Only 2 patients had 
private medical insurance. Regarding costs of living, $2252.5 
was spent on food per year on each individual ($134 was spent 
in restaurants, and money spent on items such as take-away 
food or food at work was minimal in this group of patients). 
Respondents did not report spending money on outside help with 
domestic duties or the purchase of special devices or supplies. 
The median amount spent on holidays away from home was 
$352 (including $89.7 spent on food during this period). 
The median amount for total indirect costs was $5094.4 
(IQR, $80-$17 713.6); the vast proportion of this was time 
spent on household tasks, such as cleaning, cooking, shopping, 
gardening, and childcare ($4739.1). The cost assigned to time 
spent on information seeking was $127.5. Lost working days, 
loss of education or working opportunities, and lost earnings 
were not included in the analysis because they were valued as 
0 or not reported by the majority of patients. In summary, there 
were no significant differences in total direct and indirect costs at 
baseline. With respect to some individual costs, OTC medication 
and time spent on household tasks were slightly higher in the 
tolerant group than in the reactive group (Tables 2 and 3). 
Effect of Diagnosis: Costs After the DBPCFC
We also analyzed changes in costs between reactive and 
tolerant patients 6 months after the DBPCFC (Tables 4 and 5). 
Twenty-one patients had a negative challenge and food was 
reintroduced into their diets. Comparing costs before and after 
the DBPCFC, total direct costs were significantly higher in the 
reactive group (an increase of $813.1 compared with baseline) 
than in the tolerant group (a reduction of $87.3) (P=.031) 
(Table 4). The amount spent on food was also significantly 
different (P=.040). A similar trend was also observed in 
the amount spent on medicines but the difference was not 
statistically significant. No change was observed in money 
spent on holidays. Tolerant patients also incurred lower indirect 
costs (Table 5). A greater reduction in total indirect cost was 
obtained in the tolerant group compared with the reactive group 
($538.3 vs $32.3), although the difference was not statistically 
significant.
Discussion
DBPCFC is recognized as the gold standard for food 
allergy diagnosis and has an unquestionable impact on clinical 
management. However, to date, very little has been reported on 
the economic impact of food allergy. This is the first study to 
analyze, using a validated instrument, the impact of DBPCFC 
on the socioeconomic costs of food allergy for individuals and 
households. 
Table 3. Total Indirect Annual Costs at Baseline in Geary-Khamis Dollars 
for the 42 Study Participantsa 
 Median 25th 75th  
  Percentile Percentile
Health care seeking 87.3 36.5 36.5
Time spent on  
household tasks 4739.1 3454.4 9572.5
Loss of leisure  
time (holidays) 37.7 6.8 78.5
Time spent on  
information seeking 127.5 81.4 408.2
Total indirect costs 5094.4 3727.4 9799.9  
aThe participants were also asked about the value of time spent off 
work, but the median result was 0. 
Table 2. Total Direct Annual Costs at Baseline in Geary-Khamis Dollars for the 42 Study Participants 
  Median 25th Percentile 75th Percentile
Heath care    
 Health care attention (travel+visits)a 2.7 .0 18.8 
 Paid prescription medicines 22.0 .0 72.0 
 Paid over-the-counter (OTC) medicines  161.5 .0 414.5 
 Total (prescription+OTC) 247.3 24.0 542.4
Costs of living    
 Foodb 2252.5 1217.8 3592.4
Leisure activities    
 Holidays 352.2 .0 942.1
Total direct costsc 3289.8 1079.3 4553.9
aTravel includes money spent on transportation (public transport or own car; a cost of 0 was applied to patients traveling on foot or by bicycle) and 
corresponds to the amount paid by the patient, not the cost for the health care system. 
bTotal food cost includes the cost of food at home and in restaurants, take-away food, and food purchased at work. Participants were also asked 
about money spent on outside help with domestic duties (aids or appliances) but the median amount spent was 0. 
cThis total includes additional costs (see Methods section for details). These additional costs are not fully detailed in this table because they were 
incurred by just 1 or 2 patients.
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Our study has shown that DBPCFC has an impact on direct 
costs. Six months after the challenge, patients with a confirmed 
food allergy experienced a median increase in expenditure of 
$813.1 compared with baseline. The main contribution to this 
increase was money spent on food. No significant differences 
were observed in other areas of direct costs. This observation 
could be explained by the clinical characteristics of the patients 
included in the study. Around 70% of the patients were allergic 
to milk and egg, which were the most frequent self-reported 
causes of food allergy in patients referred to allergy outpatient 
clinics in the EuroPrevall cross-sectional study. These foods are 
present in many manufactured products and allergic patients 
need to avoid even foods that contain tiny amounts used as 
preservatives or enhancers. Food labeled as “milk-egg-free” 
tends to be more expensive and patients are usually restricted to 
1 or 2 brands. Impact on food costs may be different when other 
less common allergens are involved, but it is well established 
that manufactured products that assure they do not contain a 
specific food are more expensive. No impact was observed for 
a confirmed diagnosis of food allergy on health care–seeking 
costs, probably because patients included in the study were 
using publicly funded health care. Furthermore, they typically 
travelled to the health care center on foot or by public transport. 
Good patient education at baseline visits also helps to reduce 
allergic reactions and visits to the specialist office or emergency 
room. In addition, because of the short follow-up period, it is 
possible that the patients or their carers had not yet changed 
their use of health services.
Apart from an avoidance diet, no specific therapy is 
available for food allergy, contrasting with allergic rhinitis and 
asthma, for which immunotherapy is available. Medication 
is prescribed to be used in case of reactions. This medication 
Table 4. Differences in Direct Annual Costs in Geary-Khamis Dollars Between Tolerant and Reactive Patients (n=42) 6 Months after the Double-Blind 
Placebo-Controlled Food Challenge 
   Median 25th Percentile 75th Percentile P
Health care      
 Health care attention (travel+visits) Reactive .0 -3.1 .3 .596 
  Tolerant -1.3 -12.8 13.5
Medication Reactive -4 -40 8 .409a 
  Tolerant 0 -48 6 
 Paid over-the-counter (OTC) medicines Reactive .0 -215.3 5.4 .545 
  Tolerant -64.6 -430.7 13.5 
 Paid OTC and prescription medicines Reactive -4.00 -293.03 47.84 .697 
  Tolerant -112.60 -329.51 109.46
Costs of living 
 Food   Reactive 1257.3 178.6 2766.3 .040a 
  Tolerant .0 -533.2 753.1
Leisure activities 
 Holidays Reactive .0 -234.2 513.7 .584 
  Tolerant .0 -423.1 336.5
Total direct costs Reactive 813.1 -3.7 2879.8 .031a 
  Tolerant -87.3 -521.7 211.6
aSignificant value.
Table 5. Differences in Indirect Annual Costs in Geary-Khamis Dollars Between Tolerant and Reactive Patients (n=42) 6 Months after the Double-Blind 
Placebo-Controlled Food Challenge 
  Median 25th Percentile 75th Percentile P
Health care Reactive .0 .0 .0 .57 
 Tolerant .0 .0 13.3
Time spent on household tasks Reactive -47.5 -1940.8 2485.2 .538 
 Tolerant -415.6 -3172.7 1468.7
Loss of leisure time (holidays)  Reactive .0 -6.8 45.3 .275 
 Tolerant 31.5 .0 75.6
Time spent on information seeking  Reactive -51.6 -108.5 161.3 .497 
 Tolerant 28.7 -99.7 244.8
Total indirect costs  Reactive -32.8 -2275.8 2490.7 .606  
 Tolerant -538.3 -3499.0 1845.3
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mainly consists of antihistamines and corticosteroids and in 
some cases self-injected adrenaline, which are all relatively 
cheap. Indirect costs were not significantly different between 
the groups, but tolerant patients tended to save on time spent 
on household tasks, which includes time spent shopping and 
cooking. Those activities take less time when there is no need 
to carefully read labels or avoid meals containing the offending 
allergens, for example. It was observed that loss of leisure time 
and the value of time spent on information seeking were higher, 
albeit not significantly so, in tolerant patients. This could be 
because patients who discover they are not allergic feel the 
need to reassert their new status.
The conclusions of our study may be limited by the 
small number of patients included. Despite the considerable 
difference observed for indirect costs between tolerant and 
reactive patients, the difference did not reach statistical 
significance, probably because of the reduced sample size 
and the high variability in reported costs. In addition, the 
follow-up period may have been too short to capture changes 
in lifestyle following diagnosis. These limitations may 
explain the absence of impact of DBPCFC on some of the 
cost dimensions. 
However, some strengths of the study also need to be 
mentioned. Firstly, our study recruited a sample of well-
characterized patients, with a confirmed diagnosis of food 
allergy by DBPCFC. Secondly, we assessed the socioeconomic 
impact of food allergy on individuals and households using a 
validated measurement instrument in the context of the pan-
European project Europrevall. 
DBPCFC has been considered the gold standard in food 
allergy diagnosis for a long time, but it is absent in daily 
practice in most clinical settings. In Spain it has been estimated 
that only 13% of food allergy patients are routinely diagnosed 
by an oral challenge [23]. The decision to perform an oral 
challenge, whether blind or open, is based on clinical history, 
SPT results, and sIgE values, but in some centers it may also 
be influenced by the cost of the procedure: a trained allergist 
and nurses are needed for several days (at least 3 in the case of 
a blind challenge and 1 in the case of an open challenge). This 
paper covers a new aspect to be considered in the decision on 
whether or not an oral food challenge is indicated: a negative 
result will lead to a reduction in costs of living for allergic 
individuals and households. 
Our study has focused on the economic impact of DBPCFC 
from a patient perspective. Future research is needed to assess 
the impact of DBPCFC using broader perspectives, such as 
quality of life impact and cost-effectiveness analyses.
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